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HLA typing provides essential results for stem cell and solid organ transplants, as well as
providing diagnostic beneﬁts for various rheumatology, gastroenterology, neurology, and
infectious diseases. It is becoming increasingly clear that understanding the expression of
patient HLA transcripts can provide additional beneﬁts for many of these same patient
groups. Our study cohort was evaluated using a long-read RNA sequencing methodology
to provide rapid HLA genotyping results and normalized HLA transcript expression. Our
assay used NGSEngine to determine the HLA genotyping result and normalized mRNA
transcript expression using Athlon2. The assay demonstrated an excellent concordance
rate of 99.7%. Similar to previous studies, for the class I loci, patients demonstrated
signiﬁcantly lower expression of HLA-C than HLA-A and -B (Mann–Whitney U, p value =
0.0065 and p value = 0.0154, respectively). In general, the expression of class II transcripts
was lower than that of class I transcripts. This study demonstrates a rapid high-resolution
HLA typing assay using RNA-Seq that can provide accurate HLA genotyping and HLA
allele-speciﬁc transcript expression in 7–8 h, a timeline short enough to perform the assay
for deceased donors.
Keywords: unique molecular identiﬁer (UMI), nanopore, long-read, HLA, immunogenetics allele-speciﬁc expression,
high-resolution HLA

INTRODUCTION
The application of next-generation sequencing (NGS) to human leukocyte antigen (HLA) typing has
greatly reduced the costs and time required to achieve high-resolution HLA typing (Lind et al., 2010;
Weimer et al., 2016; Cornaby et al., 2021). Currently, there are two major NGS platforms: short- and longread sequencing. Short read platforms are characterized by sequencing reads between 50 and 300 bp, while
long-read platforms can sequence reads from 150 to >2 Mb (Metzker, 2010; Jain et al., 2018). The
application of long-read technology to HLA typing has been successfully demonstrated by several
laboratories using DNA or RNA (Liu et al., 2018a; Liu, 20212018a; Lang et al., 2018; Montgomery
et al., 2019; De Santis et al., 2020; Mosbruger et al., 2020). Long read technology is beneﬁcial and applicable
for HLA typing due to various advantages of the methodology, including shorter library preparation, realtime base calling, shorter sequencing times, and potential cost savings. The main focus for rapid HLA
typing has been the development of an assay that yields high-resolution HLA typing in the time necessary
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MATERIALS AND METHODS

TABLE 1 | Cohort sociodemographic characteristics.
Characteristic
Age, Median (Range)
Gender, Count (%)
Female
Male
Race, Count (%)
African American
European American
Unknown

Values (N = 18)

Samples

53 (25–67)

Eighteen unique samples were collected in acid citrate
dextrose (ACD) blood tubes from patients undergoing
evaluation for solid organ transplantation and healthy
donors. Patient and donor demographics are characterized
in Table 1. The table describes the patient cohort age, sex,
and race distribution. We had one patient among our cohort
who did not identify with any race and is referred to as race
unknown in Table 1.

11 (61.1)
7 (39.9)
11 (61.1)
6 (33.3)
1 (5.6)

DNA Extraction and Quantitation

for deceased donor allocation. Such an assay would enable improved
virtual crossmatching and epitope analysis (Garcia-Sanchez et al.,
2020).
A challenge with Oxford Nanopore Technologies (ONT)
sequencers is the relatively higher error rate compared to
traditional short-read sequencers. Short read platforms obtain
reads with an accuracy approaching 99.99%; however, ONT
sequencers achieve between 88–94% accuracy, depending on
the chemistry and ﬂow cell used (Metzker, 2010; Liu et al.,
2021). One approach to reducing raw sequencing errors with
ONT sequencing is the attachment of random oligomers of DNA
to DNA or RNA before PCR ampliﬁcation. The incorporation of
unique molecular identiﬁers (UMIs) in the initial library
preparation has become standard for single-cell analysis (Islam
et al., 2014; Chen et al., 2018). Application of UMI to a library
enables several beneﬁts, including removal of PCR bias (Islam
et al., 2014), quantitation of input molecules (Kivioja et al., 2011;
Islam et al., 2014), and increased consensus read accuracy (Kou
et al., 2016).
There is growing evidence for the importance of HLA
expression in various diseases (Dendrou et al., 2018; Cornaby
& Weimer, 2020; Cornaby et al., 2021) and allele-speciﬁc
expression that inﬂuences T-cell activation (Gutierrez-Arcelus
et al., 2020). Allele-speciﬁc HLA expression has been studied
from single-cell sequencing data (Darby et al., 2020), and
Johansson et al. (Johansson et al., 2021) using short-read
sequencing, found variable allele-speciﬁc HLA mRNA
expression. HLA-DPB1 expression has been shown to
inﬂuence graft versus host disease (Apps et al., 2013;
Petersdorf et al., 2015). Recently, HLA expression has been
shown to impact solid organ recipient and deceased donor
immunologic compatibility (Badders et al., 2015; Montgomery
et al., 2019). However, there are no current approaches to
assess allele-speciﬁc HLA expression, protein, or transcript on
deceased donors before transplantation. With allele-speciﬁc
expression of donor antigens, virtual crossmatch predictions
could be more accurate, and patient risk stratiﬁcation could be
assessed with more granularity.
Here, we describe an assay that provides high-resolution HLA
typing and allele-speciﬁc HLA expression within the time
constraints for deceased organ donor allocation. Using RNA and
the application of UMI to quantify the mRNA HLA expression, the
data demonstrate the variability of individual HLA allele groups.
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Genomic DNA (gDNA) was isolated from peripheral blood
using Promega (Madison, WI) Maxwell RSC Whole blood
DNA kits according to the manufacturer’s instructions.
Brieﬂy, 500 µL of the buffy coat or whole blood was added
to the RSC extraction cartridge, and 75 µL of nuclease-free
water (included in the kit) was added to the elution tube. The
cartridge was loaded onto the Maxwell RSC, resulting in
isolated gDNA that was ready for downstream
applications. Genomic DNA did not undergo any
additional puriﬁcation and was quantitated using the
Quantus Fluorometer and Quantiﬂour ONE dsDNA system
by Promega (Madison, WI).

RNA Extraction and Puriﬁcation
Total RNA was isolated from peripheral blood using
Promega (Madison, WI) Maxwell RSC SimplyRNA blood
kits according to the manufacturer’s instructions.
Brieﬂy, 2.5 ml of whole blood was combined with 7.5 ml of
cell lysis solution and then incubated for 10 min at room
temperature. During this process, the red blood cells were
lysed, and the white blood cells remained intact. The solution
was spun for 10 min at 3,000 g, and the supernatant
was discarded. Two hundred microliters of chilled 1thioglycerol/homogenization solution, 200 µL of lysis buffer
and 25 µL of Proteinase K were added to the cell pellet,
mixed, and incubated at room temperature for 10 min. Ten
microliters of DNase I solution was added to the RSC
extraction cartridge in one of the chambers, and the cell
lysate was added to another. Fifty microliters of nucleasefree water (included in the kit) was added to the elution
tube. The resulting total RNA was used for downstream
applications.
Some RNA samples underwent additional puriﬁcation using
the Promega (Madison, WI) ReliaPrep RNA Cleanup and
Concentration System according to the manufacturer’s
instructions. Membrane binding solution was added to the
RNA at half the volume of the RNA (12.5 µL), and 100%
isopropanol was added at one and a half times the volume of
the RNA (37.5 µL). A series of washes and centrifugations were
performed with the provided column wash solution and RNA
wash solution, resulting in a ﬁnal elution in 15 µL with nucleasefree water.
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Measurement of RNA Quality and
Quantitation

performed using a 0.6x ratio of solid-phase reversible
immobilization (SPRI) Select beads (Beckman Coulter, Brea,
CA) and two washes with 80% EtOH. Each amplicon was
eluted off the beads with 18 µL of nuclease-free water
(Ambion Inc.). The eluate was used in the second round of
PCR, where it was combined with 25 µL of 2x Platinum SuperFi II
Green PCR master mix, 0.5 µL each of 10 µM UVP forward and
reverse primers (Resource centre, 2017), 2 µL 25 mM MgCl2 and
4 µL of nuclease-free water. Thermal cycler conditions were initial
denaturation at 98°C for 3 min, followed by ﬁve cycles of
denaturation at 98°C for 30 s, annealing with a touchdown
from 70°C to 63°C with a ramp rate of 0.2°C/s holding at 63°C
for 10 s, extension at 72°C for 90 s, ﬁve cycles of denaturation at
98°C for 20 s with an extension of 72°C for 2 min and a ﬁnal
extension at 72°C for 5 min. Another round of SPRI bead cleanup
using a 0.6x ratio and two washes with 80% EtOH was performed.
The ﬁnal round of PCR was performed using the eluate and 25 µL
of 2x Platinum SuperFi II Green PCR master mix, 0.5 µL each of
10 µM UVP forward and reverse primers, which was the same
master mix makeup that was used from the second round of
ampliﬁcation. The PCR conditions were initial denaturation at
98°C for 3 min, 25 cycles of denaturation at 98°C for 20 s with an
extension at 72°C for 90 s, and a ﬁnal extension at 72°C for 2 min.
A ﬁnal SPRI bead cleanup, as previously described, was
performed using 80% EtOH washes.

RNA fragmentation and quantitation were determined using an
Agilent (Santa Clara, CA) TapeStation 4200 RNA ScreenTape
Assay following the manufacturer’s instructions. Brieﬂy, 1 µL of
RNA was added to 5 µL of sample buffer and loaded into the
TapeStation. TapeStation plots the RNA fragment size (nt)
against the sample intensity (FU) and generates an RNA
integrity number (RIN). The TapeStation RNA ScreenTape
Assay separates, images, and analyzes RNA from 50–6,000 nt.
According to the manufacturer, the assay has a quantitative range
of 25–500 ng/μL and a quantitative precision of 10% CV. The RIN
functional range was 25–500 ng/μL. The RIN algorithm considers
the peak height of the 18S peak to the background signal to
calculate the RIN value for total RNA. RIN is on a scale of 1–10,
where 10 represents highly intact RNA and a low RIN indicates a
strongly degraded RNA sample.

cDNA Synthesis
cDNA synthesis was performed using the SuperScript IV FirstStrand Synthesis System (ThermoScientiﬁc, Waltham, MA). One
hundred nanograms of total RNA was combined with 1 µL of
10 mM dNTPs and 1 µL of 50 µM Oligo d(T)20 primer and
incubated for 5 min at 65°C and then placed on ice. A
reaction tube was made consisting of 4 µL 5x SSIV buffer, 1 µL
10 mM DTT, 1 µL Ribonuclease Inhibitor and 1 µL SuperScript
IV Reverse Transcriptase, resulting in reverse transcription (RT)
Reaction Mix. The reverse transcription (RT) reaction mix was
added to anneal RNA and then incubated at 53°C for 10 min
followed by 80°C for 10 min. This resulted in cDNA being used in
downstream applications.

Quantiﬁcation and Dilution of Amplicons
Each PCR product was analyzed with the QuBit 2.0 ﬂuorometer
(Thermo Fisher, Waltham, MA) dsDNA broad range (BR) assay.
A portion of each PCR product was diluted with nuclease-free
water to an estimated concentration of 20 ng/μL in 20 µL. A
subsequent QuBit analysis was performed with the dsDNA BR
assay to assure accurate concentrations in the library preparation.

HLA Unique Molecular Identiﬁer Assay
Library Preparation

A series of PCRs and puriﬁcations were utilized to achieve the
ﬁnal enriched PCR product, which was an HLA-locus speciﬁc
UMI amplicon. One microliter of cDNA was combined with
7.5 µL 2x Platinum SuperFi II Green PCR master mix
(ThermoScientiﬁc), 0.6 µL each of HLA gene-speciﬁc forward
and reverse UMI tagged primers at a concentration of
10 µM(Bettinotti et al., 2003; Lank et al., 2012), 0.5 µL 25 mM
MgCl2 (ThermoScientiﬁc) and 4.9 µL of nuclease-free water
(Ambion Inc., Austin, TX). Each sample had an ampliﬁcation
for HLA-A, HLA-B, HLA-C, HLA-DRB1/3/4/5, HLA-DQA1,
HLA-DQB1, HLA-DPA1, and HLA-DPB1, generating 8
amplicons per sample. PCR was performed with an initial
denaturation at 98°C for 3 min, followed by two cycles of
denaturation at 98°C for 30 s, annealing with a touchdown
from 66°C to 60°C with a ramp rate of 0.2°C/s holding at 60°C
for 60 s, and extension at 72°C for 90 s, with a ﬁnal extension of
72°C for 5 min. The ﬁrst PCR was followed by an enzymatic
removal of unincorporated gene-speciﬁc UMI primers by adding
1.5 µL of nuclease-free water and 0.75 µL each of thermolabile
exonuclease I (New England Biolabs, Ipswich, MA) and Quick
calf intestinal phosphatase (New England Biolabs) and then
incubated at 37°C for 15 min followed by enzyme inactivation
at 80°C for 2 min. To reduce off-target ampliﬁcation, cleanup was
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HLA gene-speciﬁc amplicons for one sample (8 HLA loci) were
combined into one tube in an equal molar ratio based on their
femtomolar (fmol) concentration. A total of 350–400 fmol was
targeted for each sample, and the volume was brought to 48 µL
with nuclease-free water. Libraries were prepared according to the
Native Barcoding Amplicons protocol using the Ligation
Sequencing kit (SQK-LSK109) and Native Barcoding
Expansion Kits (EXP-NBD104 and EXP-NBD114) from
Oxford Nanopore Technologies (Oxford, United Kingdom) as
follows. For a given sample, the HLA loci were pooled on an
equimolar basis. In a PCR tube, 48 µL of pooled amplicon DNA,
3.5 µL NEB Next FFPE DNA Repair Buffer (New England
Biolabs, Ipswich, MA), 2 µL NEB Next FFPE DNA Repair Mix
(New England Biolabs), 3.5 µL Ultra II End-prep reaction buffer
(New England Biolabs) and 3 µL Ultra II End-prep enzyme mix
(New England Biolabs) were combined. Samples were mixed
gently, spun down, and incubated at 20°C for 5 min and then 65°C
for 5 min. A bead-based cleanup was performed using SPRI Select
beads at a 1:1 ratio, and two washes were performed using 70%
EtOH. Samples were eluted in 25 µL of nuclease-free water and
then quantiﬁed using the QuBit dsDNA high sensitivity (HS)
assay (ThermoScientiﬁc). Each sample was given a unique
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barcode utilizing the Native Barcoding Expansion Kit. A target of
150–300 fmol in a volume of 22.5 µL for each sample was used
and combined with 2.5 µL of native barcode and 25 µL Blunt/TA
Ligase Master Mix (New England Biolabs) and was mixed by
pipetting and incubated at room temperature for 10 min. A beadbased cleanup was performed using SPRI Select beads at a 1:1
ratio (50 µL), and two washes were performed using 70% EtOH.
Samples were eluted in 26 µL of nuclease-free water and
quantiﬁed using the QuBit dsDNA HS assay. Equimolar
amounts of each barcoded sample were pooled together into a
1.5 ml tube with a target of 350–400 fmol for the pool. The pool
was brought up to 65 µL with nuclease-free water, to which 5 µL
of Adapter Mix, 20 µL 5x NEBNext Quick Ligation Reaction
Buffer (New England Biolabs), and 10 µL Quick T4 DNA Ligase
(New England Biolabs) was added, mixed gently and incubated at
room temperature for 10 min. Fifty microliters of SPRI Select
beads was added to the tube, pipetted, and incubated on a rotator
for 5 min. Tubes were placed on a magnetic rack for the beads to
pellet, and the supernatant was pipetted off. Two washes using
250 µL each of short fragment buffer from the Ligation
Sequencing Kit were performed. Final elution was performed
using 15 µL of elution buffer from the Ligation Sequencing Kit
and incubated for 10 min at room temperature. The ﬁnal library
was quantiﬁed with the QuBit dsDNA HS assay. Then, 100 fmol
of the ﬁnal library was used for sequencing. Sequencing was
performed using a MinION R10.3 ﬂow cell and loaded on the
MinION Mk1C (Oxford Nanopore Technologies) with ﬁrmware
version MinION FPGA 2.3.2 and MinKNOW version 21.02.2
using the high-accuracy basecalling module. Samples were run
individually and in batches containing up to seven pooled
samples.

(Illumina, San Diego, CA) with libraries denatured and diluted
to 20 pM, and a 1% concentration of PhiX was added. A MiSeq
cartridge with v2 chemistry and a microﬂow cell were utilized
with 2 × 150 sequencing.

Bioinformatics
All sequencing ﬁles for a patient were combined and used to
generate consensus sequences based on the minimum number of
reads grouped by UMI. Experiments used a minimum read of 1
per UMI (min1) or 10 (min10), which is a UMI group.
Additionally, using a UMI group of 1 enables PCR
deduplication. Adapters, primer sequences, and sample
barcodes were removed using porechop (Wick et al., 2018;
Hughes et al., 2020). UMI grouping was performed using
vsearch (Rognes et al., 2016), and consensus sequences were
generated using Medaka (version 1.1.3) (Xu et al., 2020).
Consensus sequences generated were used for subsequent
downstream analysis. The consensus sequence generation code
is available at https://github.com/nanoporetech/pipeline-umiamplicon/tree/cdna-no-mapping.

RNA-Seq HLA Typing and Allele-Speciﬁc
Transcript Quantitation
HLA typing was performed using (Liu et al., 2018b; Liu & Berry,
2020) a modiﬁed version of NGSEngine enabling cDNA as the
input sequence (GenDx, Chicago, IL). When performing the
assay, both pipelines were used to complement each other to
achieve the genotyping results that were generated using
NGSEngine without manual adjustments. The UMI count for
each HLA allele was generated from the number of consensus
reads, each associated with a unique UMI, which aligned to an
allele using the Athlon2 pipeline (Liu, 2021). The alignment was
implemented using minimap2 version 2.17 (Li, 2018) and cDNA
sequences from the IPD-IMGT/HLA database v3.38. The
accuracy of consensus reads from different UMI group sizes
(i.e., min1 versus min10) was calculated as a percentage of the
number of matching bases over the length of the alignment
region.

Reference HLA Genotyping
Isolated gDNA was HLA genotyped using the AlloSeq Tx17 assay
(Care Dx, Brisbane, CA). Ten microliters of gDNA with a
concentration of at least 10 ng/μL was utilized, and samples
were prepared following the manufacturer’s instructions. First,
a tagmentation step is performed on the gDNA, followed
immediately by indexing PCR, which barcodes each sample.
Double-tailed size selection and puriﬁcation with SPRI beads
(CareDx) were performed to target only the fragments of DNA of
appropriate size. Samples were then combined (pooled) with up
to 12 samples per pool. Pools were hybridized with the AlloSeq
Tx17 probe panel with a slow ramp down from 98°C to 62°C
ending with incubation at 62°C for at least 90 min and up to
overnight. The 17 probes included in the AlloSeq Tx17 are
designed to hybridize to the HLA-A, -B, -C, -E, -F, G, -H,
-DRB1, -DRB3, -DRB4, -DRB5, -DQA1, -DQB1, -DPA1,
-DPB1, MICA, and MICB loci. While the kit contains probes
for these 17 loci, the 11 classical HLA loci were used for
comparative analysis. A series of stringent washes with
suppled buffers were performed post hybridization to capture
the targets correctly. This was followed by a short enrichment
PCR and postampliﬁcation cleanup per the manufacturer’s
instructions using provided SPRI beads and 80% EtOH.
Libraries were quantitated via Qubit dsDNA BR Assay.
Sequencing was performed using the MiSeq platform
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Normalization of Unique Molecular
Identiﬁer Counts and mRNA Transcripts
To normalize UMI counts across patients, as previously described
in Johansson et al. (Johansson et al., 2021). Brieﬂy, the sum of
each HLA gene-speciﬁc UMI count was divided by the allelespeciﬁc UMI count, multiplied by the total UMI count for the
patient, and scaled to 1 million reads. The output was then
transformed using log base 2.

Statistical Analysis
Statistical analysis was performed using R (version 4.1.1) and
GraphPad Prism (version 9.3.1). One-way analysis of variance
using Geisser-Greenhouse correction, followed by the Tukey
multiple-comparisons test. Linear regression was used to
evaluate correlation with R2 values derived from the
Pearson correlation coefﬁcient. The Kruskal–Wallis test,
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FIGURE 1 | Patient sample workﬂow for RNA isolation, library preparation, and resultant HLA typing as described based on consensus sequence generation. In
short, total RNA was isolated from peripheral blood, and a portion of the total RNA was puriﬁed. RNA fragmentation and quantitation were determined, and an RNA
integrity number (RIN) was calculated for each sample. cDNA synthesis was then performed, after which PCR ampliﬁcation and puriﬁcation were utilized to achieve the
ﬁnal enriched HLA-locus speciﬁc UMI tagged amplicon. The HLA gene-speciﬁc amplicons for each patient were then used for library preparation and bar coding
with the Oxford Nanopore Technologies (ONT) platform. Sequencing was performed using the MinION R10.3 Flow Cell and loaded on the MinION Mk1C using the highaccuracy base calling module. The NGSengine bioinformatics pipeline was then utilized to provide HLA typing and Athlon2 was used to generate HLA allele-speciﬁc UMI
counts.

paired t test, independent t test, and Mann–Whitney U t test
were utilized to determine statistical signiﬁcance as
appropriate. p values that were <0.05 were considered
statistically signiﬁcant.

determined, and an RNA integrity number (RIN) was
calculated for each sample based on RNA fragment size and
sample band intensity. The RIN value is on a scale of 1–10,
where 10 represents highly intact RNA and a low RIN indicates a
more fragmented RNA sample. cDNA synthesis was then
performed, after which PCR ampliﬁcation and puriﬁcation
were utilized to achieve the ﬁnal enriched HLA-locus speciﬁc
UMI tagged amplicon. The HLA gene-speciﬁc amplicons for
each patient were then used for library preparation and
barcoding for use on the Oxford Nanopore Technologies
(ONT) platform. The ﬁnal library with a target of 100 fmol
was used for sequencing, which was performed using the
MinION R10.3 Flow Cell and loaded on the MinION Mk1C
using the high-accuracy base calling module.

4 RESULTS
Our main study objective was to further evaluate whether longread RNA sequencing could be utilized for rapid HLA
genotyping and HLA RNA transcript expression. The overall
assay schematic is shown in Figure 1. In short, total RNA was
isolated from peripheral blood, and a portion of the total RNA
was puriﬁed. RNA fragmentation and quantitation were

Frontiers in Genetics | www.frontiersin.org
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FIGURE 2 | Metrics for HLA typing using unique molecular identiﬁer-tagged RNA demonstrates that as fragmentation decreases, more reads are obtained for
sequencing, and a greater proportion of reads can be mapped to HLA loci of interest. (A) Calculated RNA integrity numbers for each patient sample with their measured
band density post isolation and clean-up. (B) Sample sequencing reads acquired and the proportion of the reads that contain recognized UMI barcodes. (C) The
proportion of reads per classical HLA locus per patient sample as counted using UMI reads. (D) The proportion of reads for each HLA locus compared to the
calculated RNA integrity number for each patient sample. (E) The percentage of cDNA reads obtained that could be mapped to the HLA loci obtained during sequencing
and their respective calculated sample RNA integrity numbers. (F) Read accuracy calculated for the minimum number of UMIs required for each HLA locus and sample
after concatenation of cDNA reads to consensus sequences. The percentage of (G) class I and (H) class II HLA-speciﬁc reads mapped compared to input isolated RNA
measured band density (****p value <0.001).

In our cohort of 18 patients, the count of different alleles was
as follows: 12 (HLA-A), 17 (HLA-B), 12 (HLA-C), 3 (HLA-DPA1),
12 (HLA-DPB1), 5 (HLA-DQA1), 5 (HLA-DQB1), 11 (HLADRB1), 3 (HLA-DRB3), 1 (HLA-DRB4), and 1 (HLA-DRB5).
Our patient median age was 53 years old, with ages ranging
from 25 to 67 years of age. Of our patients, 61.1% were female
(Table 1). Our cohort included patients of African American and
European American ethnicities, with the majority of our patients
being of African American ethnicity or descent (61.1%).

labeled, with the proportion of reads that were UMI tagged
ranging from 57.2% to 75.0% (Figure 2B).
To investigate and assess the collection of reads obtained from the
classical HLA loci, we investigated the proportion of reads mapped
to each of the classical HLA loci of the total reads sequenced
(Figure 2C). Most samples exhibited the highest proportion of
reads from the class I HLA loci HLA-A, -B, and -C, with class II
HLA loci displaying a much lower proportion of total reads on
average. To determine if sample RIN inﬂuenced the proportion of
reads obtained across the classical HLA loci, the distribution of reads
across the HLA loci was compared with the RIN value for each
patient sample (Figure 2D). The data are heterogeneous. Nearly all
samples, those with lower and higher RIN values, shared similar
distributions of sequencing reads across the HLA loci, with a higher
proportion of class I HLA loci compared to class II HLA loci.
To further evaluate whether relative amounts of RNA input
might inﬂuence the alignment ability of the assay, we compared the
TapeStation band density as measured by sample ﬂuorescent
intensity to the percentage of reads that were UMI identiﬁed and
able to be mapped to HLA loci. All of the HLA loci demonstrated a
similar trend with samples that had a higher band density also
displaying a greater proportion of reads that were able to be aligned
for class I (Figure 2E) and class II (Figure 2F). Since the band
density demonstrated this trend, we wanted to ascertain if sample
fragmentation inﬂuenced the mapping of reads to speciﬁc HLA loci.
To do this, we investigated the percentage of reads that were aligned

Metrics for cDNA-Based HLA Typing on the
ONT Platform
To better assess the quality of RNA samples obtained from our
patient samples, isolated RNA from each patient was measured by
the TapeStation 4200 (Agilent), and an RNA Integrity Number
(RIN) was calculated from the band density and sample
fragmentation (Figure 2A). Our patient samples displayed a
heterogeneous distribution of RIN values ranging from 3.0 to
8.1, with a median RIN value of 4.9. We also wanted to assess the
efﬁciency of UMI tagging in the assay. To this end, the total reads
for each patient were quantiﬁed, and the proportion of those
reads that contained a UMI was determined (Figure 2B). Samples
with higher total reads tended to have a higher proportion of
UMI. More importantly, all patient sample sequences
demonstrated that the majority of reads acquired were UMI

Frontiers in Genetics | www.frontiersin.org
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cDNA057

cDNA001

Sample ID

33:03:01

02:01:01

33:03:01

01:01:01

11:01:01

02:01:01

11:01:01

01:01:01

30:01:01

03:01:01

30:01:01

02:01:01

02:01:01

02:01:01

03:01:01

74:01:01

74:01:01

02:01:01

68:02:01

68:02:01

23:17

23:17

36:01

23:01:01

23:01:01

36:01

23:01:01

23:01:01

30:01:01

30:01:01

23:01:01

03:01:01

03:01:01

23:01:01

03:01:01

03:01:01

30:02:01

30:02:01

26:01:01

01:01:01

01:01:01

26:01:01

68:01:01

23:01:01

68:01:01

23:01:01

30:01:01

30:01:01

03:01:01

03:01:01

30:02:01

02:01:01

02:01:01

30:02:01

24:02:01

30:01:01

11:01:01

30:01:01

24:02:01

-

-

11:01:01

03:01:01

03:01:01

03:01:01

02:01:01

03:01:01

11:01:01

02:01:01

02:01:01

11:01:01

NGSEngine

02:01:01

Reference

HLA-A

56:01:01

15:10:01

40:01:02

37:01:01

44:02:01

42:01:01

51:01:01

49:01:01

15:10:01

15:03:01

-

45:01:01

53:01:01

44:03:01

44:03:01

35:01:01

44:03:01

07:02:01

47:03

08:01:01

-

44:03:01

58:02:01

42:01:01

44:03:01

07:02:01

42:01:01

35:01:01

55:01:01

40:01:02

57:02:01

53:01:01

44:03:01

07:06:01

40:01:02

35:01:01

Reference

56:01:01

15:10:01

40:01:02

37:01:01

44:02:01

42:01:01

51:01:01

49:01:01

15:10:01

15:03:01

-

45:01:01

53:01:01

44:03:01

44:03:01

35:01:01

44:03:01

07:02:01

47:03

08:01:01

-

44:03:01

58:02:01

42:01:01

44:03:01

07:02:01

42:01:01

35:01:01

55:01:01

40:01:02

57:02:01

53:01:01

44:03:01

07:06:01

40:01:02

35:01:01

NGSEngine

HLA-B

03:02:02

01:02:01

06:02:01

03:04:01

17:01:01

05:01:01

14:02:01

07:01:02

03:04:02

02:10:01

16:01:01

06:02:01

-

04:01:01

-

04:01:01

07:02:01

04:01:01

07:18:01

07:01:01

-

04:01:01

17:01:01

06:02:01

16:01:01

07:02:01

17:01:01

04:01:01

03:04:01

03:03:01

18:02:01

04:01:01

16:01:01

15:05:02

04:01:01

03:04:01

03:02:02

01:02:01

06:02:01

03:04:01

17:01:01

05:01:01

14:02:01

07:01:02

03:04:02

02:10:01

16:01:01

06:02:01

-

04:01:01

-

04:01:01

07:02:01

04:01:01

07:18:01

07:01:01

-

04:01:01

17:01:01

06:02:01

16:01:01

07:02:01

17:01:01

04:01:01

03:04:01

03:03:01

18:02:01

04:01:01

16:01:01

15:05:02

04:01:01

03:04:01

NGSEngine

HLA-C
Reference

TABLE 2 | RNA-Seq HLA typing results utilizing NGSEngine

-

01:03:01

02:01:02

01:03:01

-

01:03:01

03:01:01

01:03:01

02:02:02

02:01:01

02:01:08

01:03:01

-

01:03:01

02:01:01

01:03:01

03:01:01

02:02:02

02:02:02

01:03:01

02:01:01

01:03:01

02:02:02

02:01:01

02:01:01

01:03:01

-

01:03:01

02:01:01

01:03:01

03:01:01

01:03:01

-

01:03:01

-

01:03:01

-

01:03:01

02:01:02

01:03:01

-

01:03:01

03:01:01

01:03:01

02:02:02

02:01:01

02:01:08

01:03:01

-

01:03:01

02:01:01

01:03:01

03:01:01

02:02:02

02:02:02

01:03:01

02:01:01

01:03:01

02:02:02

02:01:01

02:01:01

01:03:01

-

01:03:01

02:01:01

01:03:01

03:01:01

01:03:01

-

01:03:01

-

01:03:01

NGSEngine

HLA-DPA1
Reference

18:01:01

04:01:01

04:01:01

01:01:01

18:01:01

04:02:01

-

04:02P

11:01:01

05:01:01

02:01:19

01:01:01

-

02:01:02

18:01:01

17:01:01

105:01:01

01:01:01

06:01:01

01:01:01

18:01:01

17:01:01

11:01P

01:01P

11:01:01

02:01:02

03:01P

04:01P

10:01P

04:01P

105:01:01

04:01:01

-

04:01:01

03:01:01

02:01:02

18:01:01

04:01:01

04:01:01

01:01:01

18:01:01

04:02:01

-

105:01:01

11:01:01

05:01:01

02:01:19

01:01:01

-

02:01:02

18:01:01

17:01:01

105:01:01

01:01:01

06:01:01

01:01:01

18:01:01

17:01:01

11:01:01

01:01:01

11:01:01

02:01:02

104:01:01

04:01:01

10:01:01

04:01:01

105:01:01

04:01:01

-

04:01:01

03:01:01

02:01:02

NGSEngine

HLA-DPB1
Reference

01:02:01

01:01:01

01:05:01

01:02:01

03:03:01

01:02:01

04:01:02

01:01:01

03:03:01

01:01:02

05:01:01

01:02:01

02:01:01

01:02:01

02:01:01

01:02:01

05:05:01

01:02:01

-

05:01:01

-

01:02:01

04:01:01

01:05:01

03:01:01

02:01:01

05:05:01

01:02:01

05:05:01

03:01:01

05:05:01

03:03:01

05:05:01

02:01:01

01:04:01

01:01:01

01:02:01

01:01:01

01:05:01

01:02:01

03:03:01

01:02:01

04:01:02

01:01:01

03:03:01

01:01:02

05:01:01

01:02:01

02:01:01

01:02:01

02:01:01

01:02:01

05:05:01

01:02:01

-

05:01:01

-

01:02:01

04:01:01

01:05:01

03:01:01

02:01:01

05:05:01

01:02:01

05:05:01

03:01:01

05:05:01

03:03:01

01:01:01

02:01:01

01:04:01

01:01:01

NGSEngine

HLA-DQA1
Reference

06:02:01

05:01:01

06:02:01

05:01:01

06:02:01

03:01:01

05:01:24

03:19:01

05:01:01

02:02:01

05:02:01

02:01:01

06:02:01

02:02:01

06:02:01

02:02:01

06:02:01

03:19:01

-

02:01:01

06:09:01

05:02:01

05:01:01

04:02:01

03:02:01

02:02:01

06:09:01

03:19:01

03:02:01

03:01:01

03:19:01

02:02:01

03:19:01

02:02:01

05:03:01

05:01:01

06:02:01

05:01:01

06:02:01

05:01:01

06:02:01

03:01:01

05:01:24

03:19:01

05:01:01

02:02:01

05:02:01

02:01:01

06:02:01

02:02:01

06:02:01

02:02:01

06:02:01

03:19:01

-

02:01:01

06:09:01

05:02:01

05:01:01

04:02:01

03:02:01

02:02:01

06:09:01

03:19:01

03:02:01

03:01:01

03:19:01

02:02:01

03:19:01

02:02:01

05:03:01

05:01:01

NGSEngine

HLA-DQB1
Reference

15:03:01

01:01:01

15:01:01

10:01:01

15:03:01

04:01:01

08:04:01

15:02P

01:02:01

07:01:01

11:01

03:01

07:01:01

11:01:02

15:03:01

07:01:01

11:02:01

15:03:01

-

03:01:01

13:31

13:02:01

12:01:01

03:02:01

07:01:01

04:01:01

13:02:01

11:02:01

04:04:01

11:01:01

-

11:01:02

07:01:01

11:02:01

14:54:01

01:01:01

15:03:01

01:01:01

15:01:01

10:01:01

15:03:01

04:01:01

08:04:01

15:02:01

01:02:01

07:01:01

11:01:02

03:01:01

07:01:01

11:01:02

15:03:01

07:01:01

11:02:01

15:03:01

-

03:01:01

13:31

13:02:01

12:01:01

03:02:01

07:01:01

04:01:01

13:02:01

11:02:01

04:04:01

11:01:01

-

11:01:02

07:01:01

11:02:01

14:54:01

01:01:01

NGSEngine

HLA-DRB1
Reference

5*01:01:01

5*01:01:01

4*01:03:01

5*01:08:01N

4*01:01:01

3*03:01:01

3*02:02:01

4*01:01:01

3*02:02:01

5*01:01:01

4*01:03:01

3*02:02:01

5*01:01:01

3*02:02:01

3*01:01:02

3*03:01:01

3*02:02:01

3*01:62:01

4*01:03:01

4*01:01:01

3*03:01:01

3*02:02:01

4*01:03:01

3*02:02:01

3*02:02:01

4*01:01:01

3*02:02:01

3*02:02:01

5*01:01:01

5*01:01:01

4*01:03:01

4*01:01:01

3*03:01:01

3*02:02:01

4*01:01:01

3*02:02:01

5*01:01:01

4*01:03:01

3*02:02:01

5*01:01:01

3*02:02:01

3*01:01:02

3*03:01:01

3*02:02:01

3*01:62:01

4*01:03:01

4*01:01:01

3*03:01:01

3*02:02:01

4*01:03:01

3*02:02:01

3*02:02:01

4*01:01:01

3*02:02:01

3*02:02:01

NGSEngine

HLA-DRB3/4/5
Reference
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FIGURE 3 | RNA expression of the patient cohort as counted by unique molecular identiﬁer. (A) The normalized UMI count distribution for each patient sample
corresponding to the calculated RNA integrity number. (B) The distribution of the normalized UMI counts across several representative patient HLA alleles and their
corresponding calculated RNA integrity numbers. All nine of these patient samples were used to evaluate interassay precision, and these data are reﬂected on the
respective patient plots. (C) Normalized UMI counts at each of the classical HLA loci (*p value <0.05, **p value <0.01). (D) The distribution of the UMI counts
obtained for each HLA allele typed for the classical HLA loci for the study patient cohort.

to HLA loci and compared those values to the patient sample RIN
value (Figure 2G). Our samples showed a wide range of reads that
could be mapped to HLA loci, ranging from 49% to 92%. While the
R2 value derived from comparing the RIN value to the percentage of

Frontiers in Genetics | www.frontiersin.org

UMI tagged reads that are mapped to HLA loci is rather poor
(Pearson r, R2 = 0.075), there does appear to be a trend that is
noticeable when examining the results (Pearson r, p value = 0.0001).
This comparison demonstrates that there could be a correlation
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between the fragmentation of samples and the ability of the samples
to be successfully aligned to HLA loci. This trend implies that HLA
loci from patient samples with a higher RIN result in a greater
proportion of reads that can be successfully mapped.

II loci, with the lowest coefﬁcient of variation of 24.27% noted for the
DRB1 locus. The expression of the other class II loci showed
variation ranging from 34.32% at DPB1 to 56.93% at the
DQA1 locus.
Of the class II loci, varying degrees of expression were observed.
DRB1 alleles demonstrated consistently high levels of transcripts and
were signiﬁcantly higher than DQB1, DQA1, and DRB3/4/5
transcripts (Mann–Whitney U, p value = 0.0139, p value =
0.0054, and p value <0.0001, respectively) but did not have
signiﬁcantly different transcript levels compared to DPA1 and
DPB1 alleles. Of interest, there was some heterogeneity in HLA
expression observed among patients in our cohort for class I and
class II (Figure 3C). For example, patient cDNA062 demonstrated
higher expression of DPB1, DQB1, and DQA1 transcripts compared
to all other loci, including HLA-A, -B, and DRB1 loci. A patient who
exhibited expression patterns that were abnormal from the pattern of
expression exhibited by the other patients was cDNA071. This
patient had DRB1, DPB1, and DPA1 transcript levels that were
equally as high as the HLA-A and -B transcripts by UMI count.
We also wanted to examine the variability of expression
between HLA alleles of the different loci (Figure 3D). It was
noted that there was greater variance observed in class II loci for
our cohort of patients compared to class I loci (Mann–Whitney
U, p value = 0.0238), with class I loci demonstrating an average
variation of 8.22% contrasted by the class II loci, which had an
average expression variation of nearly 50.59%. Of the class II loci,
the DRB1 alleles demonstrated the least amount of variance,
30.12%, and DRB3/4/5, DQB1, and DQA1 exhibited the greatest
amount of variance at 59.40%, 51.51%, and 71.63%, respectively.
To investigate whether lower input amounts of cDNA might
be responsible for the desperate variance observed between class I
and class II, 9 of the 18 samples were repeated using twice the
volume, doubling the amount of cDNA used initially. While the
doubling of input cDNA did increase the UMI count of some of
the class II transcripts, the increase was not signiﬁcantly different
for any of class I or class II HLA loci except for the DPA1 locus
(Supplementary Figure S1). Transcripts at the DPA1 locus where
transcript expression signiﬁcantly increased by 18.96% on
average (paired t test, p value = 0.034).

HLA Genotyping
As described in the Methods section and similar to other NGS
sequencing assays, this assay utilizes UMIs to tag unique transcripts
to quantity them and generate a consensus sequence of each unique
transcript. The consensus sequences are generated by grouping
sequences tagged with the same UMI. The number of reads
within a speciﬁc UMI is used to set the minimum number of
reads required to create the consensus sequence. To evaluate the
accuracy of different UMI group thresholds, the accuracy of patient
HLA typing using a minimum UMI read count of 1 (min1) and a
minimum UMI read count of 10 (min10) were evaluated
(Figure 2H). Not unexpectedly, the output consequence accuracy
was signiﬁcantly higher (p < 0.0001) for a min10 (98.7%) than for a
min1 (95.9%) (Figure 2H).
To evaluate the typing concordance of our assay, we compared
the resultant HLA genotype using the NGSengine bioinformatics
pipeline to each patient’s reference typing results (Table 2). In our
study, 18 unique patient samples, each of which was typed for 8 to
9 HLA loci per patient, provided a total typing of 314 HLA alleles.
Overall, the accuracy was 99.68% (313/314), excluding the
genotyping of a DRB5 null allele. The only discrepant typing
was one at DQA1, with the reference typing being a DQA1*05:05:
01 and the assay resulting the allele as a DQA1*01:01:01.

Expression of RNA Transcripts at Classical
HLA Class I and Class II Loci
Previous studies have evaluated using RNA-Seq to provide HLA
typing. This study evaluated both the ability to provide HLA typing
and HLA allele-speciﬁc expression using RNA-Seq. The expression
of HLA transcripts was determined by counting the UMI-tagged
HLA-speciﬁc reads and is described in detail in the methods section.
This method was based on Johansson et al.(Johansson et al., 2021)
and other allele-speciﬁc RNA-Seq expression studies. In this way, the
UMI count for all patient samples was normalized for each HLA
locus and read depth (Figure 3), the distribution of which was
examined for each patient in our cohort (Figure 3A).
When comparing the expression of transcripts, higher transcript
levels were associated with class I transcripts compared to class II
transcripts (Figure 3B). This trend appears to be independent of
sample RIN values, as samples with both high RIN and low RIN
values exhibit this pattern of expression. Figure 3B also displays the
interassay precision analysis. To this end, 16 of the 18 samples were
repeatedly tested using the same input RNA as previously utilized for
the primary patient runs. Identical typing results were obtained for
the 16 patients, and no discrepancies were noted in the second ﬁeld
of HLA typing resolution. Evaluating the precision comparing the
ﬁrst and subsequent RNA-Seq HLA locus expression results, it was
found that they were fairly similar for the class I loci, with the
variation being only 7.37%, 6.48%, and 7.28% at the HLA-A, -B, and
-C loci, respectively. There was more variation observed in the class

Frontiers in Genetics | www.frontiersin.org

DISCUSSION
Our study presents an RNA-Seq assay approach that can provide
HLA genotyping and mRNA expression levels of the classical HLA
loci as calculated by UMI counting of the HLA loci reads, which has
been demonstrated to be effective in other studies (Johansson et al.,
2021). This method displays excellent accuracy and concordance
with the NGS reference typing obtained using Illumina sequencing.
The high accuracy is in part a result of setting a minimum threshold
to ensure that a high enough number of unique UMIs are utilized to
create the allele consensus sequence that is then used to derive the
HLA genotyping. The assay had an overall HLA typing accuracy of
99.68% with one discrepant typing. Our discrepant typing was a
DQA1*05:05:01 that was called a DQA1*01:01:01. Other samples
with the same DQA1 allele were typed using our RNA-Seq method.
Upon investigation, we concluded that the discrepant typing results
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were likely related to sample collection, as repeat testing did not
resolve this particular discrepancy. There was a second typing;
however, it is not considered to be discrepant by this technique.
This typing was a DRB5*01:08:01N where no transcripts were
identiﬁed by RNA-Seq, even after repeat testing was performed.
While mRNA transcripts of this null allele are likely produced,
transcript levels were likely extremely low, possibly due to
intracellular degradation as a result of its early transcript
termination (Voorter et al., 1997; Barsakis et al., 2019). This is a
limitation for any RNA-based HLA typing method compared to a
genomic DNA NGS typing method. It is possible that null alleles
with highly degraded or no mRNA expression would fail to be typed
due to the nature of the typing methodology. This would have low to
no clinical impact as null alleles do not demonstrate surface
expression on donor tissue. As this is the case, not providing
typing for null alleles would not impact clinical practice or
patient outcomes in any way. However, the assay does perform
well with relatively low transcript levels. Deceased donor typing or
smaller batched runs should have less difﬁculty with low transcript
levels as more reads can be acquired, increasing the depth of
coverage, which should ameliorate this problem. We also had
several samples where one allele portion was extremely low,
ranging between 8.1% and 18.9% of all reads aligned to the locus.
Eight of the nine (88.9%) samples where this low allele proportion
was observed occurred at the DQA1 locus with the remnant one at
the HLA-B locus.
As we have observed in our patient cohort and from other
studies investigating the expression of HLA loci, DQA1 is one of
the classical HLA loci with the lowest amount of mRNA
expression (Johansson et al., 2021). As a result, it is not
surprising that this HLA locus resulted in a discrepancy and
that this was also the HLA locus that demonstrated the most
allelic imbalance for several samples. Additionally, this could be
the result of batching many patients per run using this method. If
this method were performed for just one or two donors per ONT
run, as would normally be performed for deceased donor typing
by other methods, more reads could be obtained per patient
sample, and the likelihood of dropout, allelic imbalance, or
mistyping as a result of low transcript levels could be mitigated.
Aside from HLA genotyping, this RNA-Seq method also
provides HLA allele mRNA transcript expression. Nearly all of
our patient samples had a greater amount of UMI-counted reads
from the class I HLA loci HLA-A, -B, and -C, with class II HLA
loci displaying a lower proportion of total reads on average. These
ﬁndings are consistent with what we would expect given the
difference in the proportion of cells in the peripheral blood. We
would expect that since our RNA was extracted from peripheral
blood, there should be more class I mRNA transcripts than class
II transcripts given the larger proportion of class I-expressing
cells compared to class II-expressing cells. Our experimental
results are similar to those of Johansson et al., who also
utilized an RNA-Seq method to investigate HLA transcript
levels (Johansson et al., 2021). As in their study, we found that
class I locus transcripts were more abundantly expressed than
class II transcripts. However, in our cohort of patients, we found
that of our class I alleles, both the HLA-A and -B loci have higher
expression than HLA-C. Their study cohort demonstrated lower
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transcripts of HLA-A, with HLA-C having the highest amount of
transcripts of all the HLA loci that they evaluated. This difference
is likely due to the population demographic differences between
the studies. There is evidence that the HLA haplotype is more
associated with HLA-C mRNA expression than with allotype or
polymorphisms (Bettens et al., 2014). Additionally, it has been
demonstrated that age likely inﬂuences HLA mRNA transcript
levels for HLA class I loci (le Morvan et al., 2001).
This could also be related to the difference in methodology
utilized between the studies. The method utilized by Johansson
et al. uses a UMI that is attached to the 5′ end of the RNA
transcripts using a template-switching oligo (TSO) during ﬁrststrand synthesis. This is then followed by ampliﬁcation of the fulllength cDNA. Our method performs cDNA synthesis as usual per
the manufacturer’s instructions and then attaches the UMI to the
5′ end of the transcript after cDNA is synthesized and during
PCR enrichment instead. We found that by attaching the UMI
during the PCR enrichment step rather than during cDNA
synthesis, we were able to obtain a higher UMI labeling
efﬁciency. However, this difference in protocol might explain,
at least in part, the different class I mRNA expression results
observed in our patient samples.
However, the class II ﬁndings between this study and that of
Johansson et al. are extremely similar. Our study provides mRNA
expression data for the DRB3/4/5 loci. While the expression of
mRNA transcripts at the DRB5 locus is fairly heterogeneous, the
DRB3 and DRB4 loci demonstrate much less variance of expression.
However, for most patients, these transcripts are some of the least
abundant measured HLA loci examined. These results are
concordant with studies that have investigated the expression of
DRB3/4/5 and compared it to the expression of mRNA transcripts at
DRB1, mainly showing that DRB1 transcripts are typically more
abundant in lymphocytes than DRB3/4/5 transcripts (Emery et al.,
1993; Faner et al., 2010).
This assay does display increased variance between patient
samples at the DPB1, DPA1, DQB1, and DQA1 loci. This
variance is likely a consequence of two factors. First, it is
known that these loci exhibit lower expression than other HLA
loci in certain patients and could also be due to allele-speciﬁc
transcript expression, resulting in higher variance between
patient samples. Second, these class II loci transcripts are
only expressed by antigen presenting cells, which likely
represent the minority of cells from which RNA was
harvested. The proportion of these cells in the peripheral
blood could also be different between patients, resulting in
the high variance observed between patient samples that share
the same DP and DQ alleles.
The mRNA expression obtained with this type of assay can
contribute in several areas of transplant medicine. Quantiﬁcation,
or even just relative quantitation, of mRNA transcripts for each
locus of a patient can assist in improving the evaluation for donor
organ rejection based on the immunologic risk proﬁle of the
selected recipient. While elevated mRNA transcript levels do not
always ensure elevated protein levels, there is an association that
most elevated transcript levels result in elevated translation of
transcripts into protein. As a result, understanding which
transcripts are highly elevated can help predict which proteins
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would most likely be most prevalent on the surface of donor cells.
As an example, in general, we expect that HLA-C is less expressed
on the cell surface and is also typically less immunogenic;
however, one of our patients displayed the highest count of
mRNA transcripts for one of the HLA-C alleles compared to
all other loci. These ﬁndings could suggest that the HLA-C loci for
this patient might be more immunogenic due to the probably
elevated amounts of allelic HLA-C expressed for the donor or that
it might be more prudent to identify a matching donor at the
HLA-C locus to alleviate potentially more risk at this HLA locus.
This same principle could apply to any of the HLA loci where
elevated levels of mRNA transcription might suggest an increased
immunologic risk for donor-recipient pairs.
These assay results are extremely encouraging considering
that both highly accurate HLA genotyping and RNA expression
were able to be derived from samples that showed both low and
high RIN values. Sometimes obtaining samples or utilizing
different sample types for DNA- or RNA-based assays can be
rather challenging. Understanding that this assay can provide
reliable results even from highly fragmented RNA samples
allows for the possibility that this assay could be used to
provide HLA typing and gene expression on alternate sample
types where RNA yield is very fragmented, such as in the case of
RNA isolation from formalin-ﬁxed parafﬁn-embedded (FFPE)
tissue samples (Levin et al., 2020; Shi et al., 2021). This would
allow laboratories to obtain HLA typing and transcript
expression from tissue biopsy samples if there were the need
to investigate patient physical crossmatch and HLA antibody
test results. While our most fragmented samples with RIN
values of 3 were able to achieve accurate HLA typing results,
it is likely that samples with lower RIN values, exhibiting even
more fragmentation, have an increased risk of HLA typing
failure.
These results could assist in providing more accuracy and
sensitivity for virtual crossmatch determinations (Garcia-Sanchez
et al., 2020). By understanding the relative transcript levels or
proportion of HLA allele transcript counts, centers would have
the ability to use preexisting HLA antibody testing data to better
identify which donor antigens are likely to result in a positive
physical crossmatch given levels of mRNA expression
(Montgomery et al., 2019; Weimer & Newhall, 2019). If a
donor has relatively low amounts so mRNA transcripts of a
given allele(s) that would otherwise have been assumed to be
higher, a negative crossmatch determination could be made with
higher conﬁdence. The inverse of this would also be likely true as
well, with abnormally increased mRNA transcripts observed, a
positive crossmatch could be predicted with a higher level of
conﬁdence. This assay is a tool for enabling a better
understanding of how allele-speciﬁc HLA transcript expression
impacts transplant compatibility and outcomes. More studies are
needed to elicit the exact nature of how HLA transcript levels
impact immunologic compatibility.
A ﬁnal advantage to utilizing this assay for clinical typing in
the future is the advantage of turnaround times. Using the ONT
platform, the assay has a turnaround time of 7–8 h from receipt of
the sample in the laboratory to evaluation of ﬁnal HLA typing
results and HLA mRNA expression levels. This is shorter than the
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time required for current NGS methods used in the clinical
transplant medicine laboratory, which normally requires
approximately 18–24 h based on the NGS method utilized.
Compared with AlloSeq hybrid capture NGS HLA typing, this
assay is quite rapid (Figure 1), providing complete HLA typing
and transcript expression in 6.5–7 h. Compared to the most rapid
methods of obtaining deceased donor typing using real-time
polymerase chain reaction (RT–PCR) or sequence-speciﬁc
oligonucleotide (SSO), this assay is slightly more time
consuming by several hours. However, the additional
information gained, high resolution typing and donor HLA
transcript expression would be beneﬁcial and worth the
additional assay time. With this RNA-Seq workﬂow timeline, a
deceased donor could be typed, and HLA mRNA expression
levels could be calculated to provide this additional information
to better help transplant centers assess the immunologic risk of a
donor-recipient pair. Additionally, donor transcript expression in
conjunction with recipient anti-HLA antibody status could be
utilized together to provide better virtual crossmatch predictions
(Montgomery et al., 2019). The assay could also be utilized for
typing living donors. Our patients were typed using batches of up
to seven patients. However, the assay has the potential to be scaled
up to accommodate a higher number of patient batches if
necessary.
n this study, we describe a novel assay that provides highresolution HLA typing and allele-speciﬁc HLA expression
within the time constraints for deceased organ donor
allocation. While the assay may not provide immediate
beneﬁts for the current organ allocation scheme, it would
provide additional important information for transplant
centers to utilize when deciding if an organ donor would be
appropriate for their recipient. Currently, the United States
United Network for Organ Sharing (UNOS) instructs that six
antigen-matched organs be given elevated priority. While only a
small portion of deceased donor kidneys are well matched, this
assay would help provide additional information about the
patient typing and potential protein expression that will
allow individual centers to risk stratify their candidates for
the organ offer with this additional information. The assay
demonstrates reliable HLA typing performance even with
samples that exhibit a high degree of fragmentation. This has
major implications for the transplant laboratory, which often
receives patient samples that are not of the highest quality but
must be utilized due to time constraints or a lack of better
patient samples. Additionally, using this method, it might be
possible to provide typing for donors from FFPE slides or tissue
samples that display a high degree of fragmentation. Utilizing
RNA and the application of UMI counting to quantify the
mRNA HLA expression, the data demonstrate the variability
of individual HLA allele groups among individuals. The assay
results may be essential in both solid organ and hematopoietic
stem cell transplants as well other areas of medicine in providing
additional information to further evaluate and risk-stratify
donor and recipient pairs.
Our study is limited in that it used peripheral blood cells for
HLA transcript expression. As described earlier in the article, this
is likely why there is an increased amount of class I mRNA
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transcripts compared to class II transcripts. There is no way to
adequately predict how the cellular components of each patient
inﬂuenced the mRNA transcript levels calculated, but this likely
inﬂuenced the transcript expression of each patient. A ﬁnal
limitation was that our study was restricted to only a small
cohort of patients.
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